Abstract: Bullous systemic lupus erythematosus (BSLE) is a rare autoimmune subepidermal blistering disease, with few cases described in childhood. It has different clinical-pathological features. We report a case of BSLE in a 10-year-old child with systemic lupus erythematosus, treated with prednisone and hydroxychloroquine. There was complete remission with dapsone, with no recurrence of skin lesions throughout one year of follow-up. We highlight the rarity and early age of occurrence.
INTRODUCTION
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous manifestation of systemic lupus erythematosus (SLE), and even more uncommon in the pediatric population 1, 2 It is a heterogenous disease, caused by autoantibodies against the dermo-epidermal junction, particularly type VII collagen. 3 Occasionally, other autoantigens, such as laminin 5, laminin 6 and BP230 are described. 4 BSLE presents a distinct combination of clinical, histological, immunopathological and electron microscopy features. 5 We report a case of BSLE in a 10-year-old child with SLE, under immunosuppressive treatment with prednisone and hydroxychloroquine for 4 months.
We highlight the rarity, due to the fact that it developed during childhood, in a patient under standard SLE treatment.
CASE REPORT
A 10-year-old female patient, weighing 31 kg was being followed for SLE over the previous 4 months, on prednisone (60 mg/ day) and hydroxychloroquine (130 mg/day). She developed tense, isolated and grouped vesiculobullous lesions on the face, neck, axillae, upper limbs, inguinal region, buttocks and oral, nasal and genital mucosa, over 1 week (Figures 1 to 3) . She also had occasional fever and hepatomegaly. The patient remained stable during 1 year of follow-up.
DISCUSSION
BSLE is a rare bullous variant, 1,3-6 affecting less than 5% of SLE patients. 6 It is even more uncommon in the pediatric population and presents rarely as the initial manifestation of lupus erythematosus. 6 In our case, the bullous disease manifested 4 months after the diagnosis and commencement of treatment for SLE.
Clinically, BSLE is characterized by a generalized vesiculobullous eruption, non-cicatricial, restricted to photo-exposed areas, The activity of the bullous disease can occur isolated from or concomitantly with other systemic manifestations of SLE, nephritis and serositis in particular. 1, 2 Therefore, in all cases of BSLE, we should always monitor systemic changes, as in SLE. 5 In our case, raised levels of antinuclear antibodies, hypocomplementemia, anemia, mild proteinuria and pleural and pericardial effusion were seen, indicating active SLE and emphasizing the role of the dermatologist in the identification and early diagnosis of these abnormalities.
The main differential diagnoses of BSLE are acquired epidermolysis bullosa, dermatitis herpetiformis, bullous pemphigoid and linear IgA bullous dermatosis. 5 However, the clinical presen-
